Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 11/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28062609 | 0.86 | POLB (0.31) | — | |
| SCHEMBL17865487 | 0.81 | CES2 (0.40) | CES2CES1MDM2RIPK1 | |
| SCHEMBL28037292 | 0.75 | CES2 (0.36) | CES2CES1RIPK1 | |
| SCHEMBL28037291 | 0.75 | CES2 (0.36) | CES2CES1RIPK1 | |
| SCHEMBL15524582 | 0.71 | CES2 (0.44) | CES2CES1MDM2 | |
| SCHEMBL30939744 | 0.71 | CES2 (0.44) | CES2CES1MDM2 | |
| SCHEMBL18852418 | 0.70 | CES2 (0.47) | CES2CES1MDM2 | |
| SCHEMBL12761889 | 0.70 | CTSS (0.45) | CES2CES1 | |
| SCHEMBL17102135 | 0.70 | CES2 (0.39) | CES2CES1MDM2ANO1 | |
| SCHEMBL30589585 | 0.70 | CTSS (0.45) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106632349-B | The hydrate and its preparation and application of the salt of pyran derivate or its salt | 海思科医药集团股份有限公司 | 2019-05-28 | — | — | CN | disclosed |
| CN-105085530-B | Ternary condenses cyclosubstituted amino hexatomic ring analog derivative and its application in medicine | 四川海思科制药有限公司 | 2019-01-04 | — | — | CN | disclosed |
| CN-105294694-B | Amino hexatomic ring analog derivative and its application in medicine | 四川海思科制药有限公司 | 2019-01-04 | — | — | CN | disclosed |
| CN-105518008-B | Amino pyrans ring derivatives and combinations thereof and application | 海思科医药集团股份有限公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-105531277-B | Pyrrolo-imidazole ring derivatives and their use in medicine | 四川海思科制药有限公司 | 2018-03-02 | — | — | CN | disclosed |
| CN-106632349-A | Pyran derivative salts or hydrates thereof, and preparation and applications of the salts and the hydrates | 四川海思科制药有限公司 | 2017-05-10 | — | — | CN | disclosed |
| US-9481680-B2 | Process for the preparation of key intermediates of omarigliptin | F.I.S.—FABBRICA ITALIANA SINTETICI S.P.A (IT) | 2016-11-01 | — | — | US | disclosed |
| US-20160200727-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES OF OMARIGLIPTIN | F.I.S.- FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2016-07-14 | — | — | US | disclosed |
| EP-2997008-B1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES OF OMARIGLIPTIN | ITALIANA SINT SPA (IT) | 2016-06-29 | — | — | EP | disclosed |
| CN-105531277-A | Pyrrolo-imidazole ring derivatives and their use in medicine | SICHUAN HAISCO PHARMACEUTICAL CO LTD | 2016-04-27 | — | — | CN | disclosed |
| CN-105518008-A | Amino pyranoid ring derivative and composition and use thereof | SICHUAN HAISCO PHARMACEUTICAL CO LTD | 2016-04-20 | — | — | CN | disclosed |
| EP-2997008-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES OF OMARIGLIPTIN | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2016-03-23 | — | — | EP | disclosed |
| CN-105294694-A | Amino hexatomic ring derivative and application thereof to medicine | SICHUAN HAISCO PHARMACEUTICAL CO LTD | 2016-02-03 | — | — | CN | disclosed |
| CN-105085530-A | Fused tricyclic substituted amino six-membered ring derivative and application thereof in medicine | SICHUAN HAISCO PHARMACEUTICAL CO LTD | 2015-11-25 | — | — | CN | disclosed |
| CN-105037367-A | Amino six-membered ring derivative and application thereof in medicines | SICHUAN HAISCO PHARMACEUTICAL CO LTD | 2015-11-11 | — | — | CN | disclosed |
| WO-2015139859-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES OF OMARIGLIPTIN | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200727-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES OF OMARIGLIPTIN | SI, OSTC, VIP | CES2 3492/4885CES1 811/4885MDM2 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.